Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer
Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosome...
Saved in:
| Published in | Journal of translational medicine Vol. 19; no. 1; pp. 103 - 10 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
09.03.2021
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1479-5876 1479-5876 |
| DOI | 10.1186/s12967-021-02768-8 |
Cover
| Abstract | Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named “cytosomes”. While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. |
|---|---|
| AbstractList | Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named “cytosomes”. While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. Abstract Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named “cytosomes”. While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named “cytosomes”. While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. Exosomes are nanoparticle sized (100 [+ or -] 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named "cytosomes". While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. Keywords: Exosomes, Cancer, Cytosomes, Signaling, Reprogramming, Therapy Exosomes are nanoparticle sized (100 [+ or -] 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named "cytosomes". While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named "cytosomes". While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells.Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. In addition, exosomes can be used as a drug delivery system and may be very effective at reducing toxicity and increasing bioavailability of therapeutic molecules and drugs. Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. Extensive research has been performed specifically using amniotic fluid-derived extracellular vesicles, named "cytosomes". While the use of cytosomes in clinical application is still in the early stages, researchers have shown great potential for these EVs in regenerative medicine as immune modulators, in controlling microbial infection and by inducing tissue repair through the activation of endogenous, tissue-specific stem cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells. |
| ArticleNumber | 103 |
| Audience | Academic |
| Author | Olalde, Jose Kweh, Mercedes F. White, Ian A. Biava, Pier Mario Gonzalez, Michael J. Goldschmidt-Clermont, Pascal J. Toro, Alondra P. |
| Author_xml | – sequence: 1 givenname: Michael J. surname: Gonzalez fullname: Gonzalez, Michael J. organization: Medical Sciences Campus, School of Public Health, University of Puerto Rico, School of Medicine, Chiropractic Program, Universidad Central del Caribe – sequence: 2 givenname: Mercedes F. surname: Kweh fullname: Kweh, Mercedes F. organization: Neobiosis, LLC – sequence: 3 givenname: Pier Mario surname: Biava fullname: Biava, Pier Mario – sequence: 4 givenname: Jose surname: Olalde fullname: Olalde, Jose organization: Centro Medicina Regenerativa (CMR) – sequence: 5 givenname: Alondra P. surname: Toro fullname: Toro, Alondra P. organization: Department of Biology, University of Puerto Rico – sequence: 6 givenname: Pascal J. surname: Goldschmidt-Clermont fullname: Goldschmidt-Clermont, Pascal J. organization: Alzady International, LLC – sequence: 7 givenname: Ian A. orcidid: 0000-0002-6078-0489 surname: White fullname: White, Ian A. email: ianwhite@ufl.edu organization: Neobiosis, LLC |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33750417$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhU1JaR7tH-iiGLrpxqkk67kphJC2gUA2LV2Ka_na0WBbU8kzJP--mpmkyYQQjLC4-s6x79U5Lg6mMGFRfKTklFItvybKjFQVYTQvJXWl3xRHlCtTCa3kwZP9YXGc0oIQxgU374rDulaCcKqOij8XaxhWMPswlaEr8TakMGLZYvTrXF1jKiGVjQ-Vn7oQxy0JQxlxGUMfYRz91JfzDUZY3pWZKB1MDuP74m0HQ8IP9--T4vf3i1_nP6ur6x-X52dXlZNEzZVWLekUV4q1uoWGg1NInWqMAVUTIZkCbLlQinYu_z1DRpAbTTVFptCY-qS43Pm2ARZ2Gf0I8c4G8HZbCLG3EGfvBrSNoKYVQjfOMd4wY4hgrQFXoyFSg85e33Zey1UzYutwmiMMe6b7J5O_sX1YW2U4lzXPBl_uDWL4u8I029Enh8MAE4ZVsiwPva6NYBv08zN0EVYxT3ZLMUMNZfUj1UNuYHMD-btuY2rPpMg-UhqRqdMXqPy0OHqXM9P5XN8TfHra6P8OH2KRAb0DXAwpReys8_P26rOzHywldpNAu0ugzQm02wTazRDZM-mD-6uieidKGZ56jI_TeEX1D3TL7JU |
| CitedBy_id | crossref_primary_10_52586_4975 crossref_primary_10_1002_mrd_23550 crossref_primary_10_3389_fimmu_2022_1002742 crossref_primary_10_3892_ijmm_2023_5320 crossref_primary_10_15212_AMM_2022_0024 crossref_primary_10_1186_s12943_024_01932_0 crossref_primary_10_2174_0115680266304636240626055711 crossref_primary_10_1016_j_snb_2025_137578 crossref_primary_10_1186_s41065_024_00346_8 |
| Cites_doi | 10.1021/acs.analchem.0c01373 10.1021/mp700113r 10.1093/neuonc/noaa254 10.3389/fonc.2014.00127 10.3727/096504005776449716 10.3390/biomedicines9020146 10.1016/j.mehy.2016.07.009 10.1002/jcb.24073 10.1172/JCI81135 10.3390/ijms20092151 10.17140/EPOJ-5-118 10.1080/15476286.2016.1259061 10.1158/0008-5472.CAN-17-1493 10.2174/1389201016666150629102825 10.1126/science.aau6977 10.2174/092986709788803312 10.1002/pmic.201200533 10.1039/C7CS00330G 10.1007/s10571-015-0296-1 10.1016/j.biomaterials.2013.11.083 10.2174/138920111794295864 10.1186/s40880-019-0393-5 10.1021/acs.molpharmaceut.9b00104 10.1016/j.tcb.2013.09.011 10.1371/journal.pone.0169899 10.3390/cells9030755 10.1021/acs.molpharmaceut.8b00277 10.1016/j.semcdb.2017.01.003 10.1016/0092-8674(83)90040-5 10.1186/s13578-019-0282-2 10.3389/fgene.2019.00367 10.1007/s11095-014-1593-y 10.1158/1078-0432.CCR-15-2170 10.2174/092986732533181024105122 10.18632/oncotarget.13499 10.7150/thno.18133 10.1016/j.canlet.2009.02.011 10.18632/oncotarget.3598 10.3390/dj7020048 10.18632/oncotarget.5192 10.1007/s12195-016-0457-4 10.7150/ijbs.27796 10.1038/ncb1725 10.3390/foods6100092 10.1158/0008-5472.CAN-08-3860 10.1038/mt.2012.180 10.1007/s00418-016-1460-5 10.1016/j.semcancer.2017.02.006 10.12998/wjcc.v7.i2.171 10.1007/s00018-014-1764-3 10.1111/j.2042-7158.2012.01567.x 10.1016/S0140-6736(02)09552-1 10.1016/j.biocel.2012.08.007 10.1007/s10911-020-09473-0 10.1007/s12015-010-9166-x 10.1089/scd.2012.0304 10.3322/caac.21492 10.1186/s12943-015-0327-z 10.1016/j.semcdb.2015.02.010 10.1016/j.mam.2017.12.003 10.1186/s13046-019-1317-6 10.1055/s-0030-1267043 10.3390/ijms21010052 10.1038/s41598-018-38320-w 10.3390/ijms21165840 10.1111/cpr.12659 10.21037/atm.2017.01.50 10.1002/cncr.27895 10.1074/mcp.RA117.000267 10.1007/s10495-006-8895-4 10.1080/20013078.2018.1505403 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12967-021-02768-8 |
| DatabaseName | Springer Nature Link CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest One Academic ProQuest One Academic (New) ProQuest - Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_b519d558bcc24b299052d9ac3e9068a8 PMC7944634 A655246695 33750417 10_1186_s12967_021_02768_8 |
| Genre | Journal Article Review |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7T5 7XB 8FK AZQEC COVID DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-87d0f74772d8dab4ac7e1c7b99a7305627aed45771fc0242e20e498181e27e993 |
| IEDL.DBID | M48 |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:28:55 EDT 2025 Thu Aug 21 18:22:42 EDT 2025 Fri Sep 05 13:35:26 EDT 2025 Fri Jul 25 03:12:07 EDT 2025 Tue Jun 17 21:09:48 EDT 2025 Tue Jun 10 20:42:43 EDT 2025 Thu Apr 03 07:00:07 EDT 2025 Tue Jul 01 03:51:16 EDT 2025 Thu Apr 24 23:10:05 EDT 2025 Sat Sep 06 07:28:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Signaling Therapy Cytosomes Reprogramming Exosomes Cancer |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-87d0f74772d8dab4ac7e1c7b99a7305627aed45771fc0242e20e498181e27e993 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-6078-0489 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-021-02768-8 |
| PMID | 33750417 |
| PQID | 2502919123 |
| PQPubID | 43076 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b519d558bcc24b299052d9ac3e9068a8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7944634 proquest_miscellaneous_2504339524 proquest_journals_2502919123 gale_infotracmisc_A655246695 gale_infotracacademiconefile_A655246695 pubmed_primary_33750417 crossref_citationtrail_10_1186_s12967_021_02768_8 crossref_primary_10_1186_s12967_021_02768_8 springer_journals_10_1186_s12967_021_02768_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-09 |
| PublicationDateYYYYMMDD | 2021-03-09 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAbbrev | J Transl Med |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | S Ohno (2768_CR54) 2013; 21 H Wu (2768_CR45) 2016; 7 TN Lamichhane (2768_CR53) 2016; 9 C Junquera (2768_CR36) 2016; 146 C Quezada (2768_CR23) 2018; 60 JE Pullan (2768_CR52) 2019; 16 P Anand (2768_CR47) 2007; 4 L Gong (2768_CR62) 2019; 39 JL Hood (2768_CR42) 2016; 94 X Chen (2768_CR34) 2019; 10 2768_CR43 VR Minciacchi (2768_CR21) 2015; 6 F Mannavola (2768_CR31) 2019; 21 Z Wu (2768_CR32) 2019; 52 F Andre (2768_CR57) 2002; 360 L Einhorn (2768_CR68) 1983; 4 D Choi (2768_CR37) 2017; 67 F D’Anselmi (2768_CR74) 2011; 12 R Ayuzawa (2768_CR77) 2009; 280 JA Tickner (2768_CR58) 2014; 4 Y Tanaka (2768_CR14) 2012; 119 SJ Hewlings (2768_CR46) 2017; 6 2768_CR70 Y Zhang (2768_CR4) 2019; 9 CY Fong (2768_CR76) 2011; 1 D Di Vizio (2768_CR20) 2009; 69 R Kalluri (2768_CR8) 2020; 367 CH Wong (2768_CR40) 2019; 7 PM Biava (2768_CR73) 2002; 17 K Al-Nedawi (2768_CR16) 2008; 10 C Bang (2768_CR55) 2012; 44 B You (2768_CR2) 2018; 8 J Rak (2768_CR17) 2010; 36 C Ciardiello (2768_CR28) 2019; 38 K Gauthaman (2768_CR78) 2012; 113 IA White (2768_CR11) 2020; 5 M Hunsaker (2768_CR33) 2019; 7 2768_CR24 VR Minciacchi (2768_CR30) 2017; 77 S Atay (2768_CR35) 2018; 17 2768_CR69 2768_CR26 T Eguchi (2768_CR27) 2020; 9 A Cucina (2768_CR71) 2006; 11 VR Minciacchi (2768_CR19) 2015; 40 B Baquir (2768_CR56) 2017; 5 PM Biava (2768_CR61) 2014; 21 K O'Brien (2768_CR59) 2015; 6 2768_CR65 S Bruno (2768_CR66) 2013; 22 Y Zhang (2768_CR6) 2019; 9 H Liang (2768_CR15) 2015; 14 B-T Pan (2768_CR3) 1983; 33 T Vagner (2768_CR29) 2018; 7 AJ Federation (2768_CR64) 2014; 24 T Livraghi (2768_CR67) 2005; 15 TB Steinbichler (2768_CR41) 2017; 44 G Kibria (2768_CR44) 2018; 15 D De (2768_CR63) 2017; 46 P Li (2768_CR13) 2017; 7 LT Brinton (2768_CR5) 2015; 72 A Conley (2768_CR25) 2017; 14 MJ Gonzalez (2768_CR60) 2018; 33 T Yang (2768_CR51) 2015; 32 F Di Giuseppe (2768_CR18) 2021; 9 L Antounians (2768_CR79) 2019; 9 O Tacar (2768_CR49) 2013; 65 C Carvalho (2768_CR48) 2009; 16 2768_CR1 R Kalluri (2768_CR12) 2016; 126 F Shiri (2768_CR22) 2020; 92 S Principe (2768_CR39) 2013; 13 PM Biava (2768_CR75) 2018; 25 T Huang (2768_CR7) 2019; 15 Q Wang (2768_CR10) 2017; 74 W Olejarz (2768_CR9) 2020; 21 2768_CR50 E D'Asti (2768_CR38) 2016; 36 PM Biava (2768_CR72) 1977; 12 |
| References_xml | – volume: 92 start-page: 9866 issue: 14 year: 2020 ident: 2768_CR22 publication-title: Anal Chem doi: 10.1021/acs.analchem.0c01373 – volume: 4 start-page: 807 issue: 6 year: 2007 ident: 2768_CR47 publication-title: Mol Pharm doi: 10.1021/mp700113r – ident: 2768_CR26 doi: 10.1093/neuonc/noaa254 – volume: 4 start-page: 127 year: 2014 ident: 2768_CR58 publication-title: Front Oncol doi: 10.3389/fonc.2014.00127 – volume: 15 start-page: 399 issue: 7–8 year: 2005 ident: 2768_CR67 publication-title: Oncol Res doi: 10.3727/096504005776449716 – volume: 9 start-page: 146 issue: 2 year: 2021 ident: 2768_CR18 publication-title: Biomedicines doi: 10.3390/biomedicines9020146 – volume: 94 start-page: 118 year: 2016 ident: 2768_CR42 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2016.07.009 – volume: 113 start-page: 2027 issue: 6 year: 2012 ident: 2768_CR78 publication-title: J Cell Biochem doi: 10.1002/jcb.24073 – volume: 126 start-page: 1208 issue: 4 year: 2016 ident: 2768_CR12 publication-title: J Clin Invest doi: 10.1172/JCI81135 – ident: 2768_CR70 doi: 10.3390/ijms20092151 – volume: 33 start-page: 4 year: 2018 ident: 2768_CR60 publication-title: J Orthomol Med. – volume: 5 start-page: 8 issue: 1 year: 2020 ident: 2768_CR11 publication-title: Epidimiol Open J doi: 10.17140/EPOJ-5-118 – volume: 14 start-page: 305 issue: 3 year: 2017 ident: 2768_CR25 publication-title: RNA Biol doi: 10.1080/15476286.2016.1259061 – volume: 77 start-page: 3961 issue: 14 year: 2017 ident: 2768_CR30 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1493 – ident: 2768_CR69 doi: 10.2174/1389201016666150629102825 – volume: 367 start-page: 6 year: 2020 ident: 2768_CR8 publication-title: Science doi: 10.1126/science.aau6977 – volume: 16 start-page: 3267 issue: 25 year: 2009 ident: 2768_CR48 publication-title: Curr Med Chem doi: 10.2174/092986709788803312 – volume: 13 start-page: 1608 issue: 10–11 year: 2013 ident: 2768_CR39 publication-title: Proteomics doi: 10.1002/pmic.201200533 – volume: 46 start-page: 6241 issue: 20 year: 2017 ident: 2768_CR63 publication-title: Chem Soc Rev doi: 10.1039/C7CS00330G – volume: 36 start-page: 383 issue: 3 year: 2016 ident: 2768_CR38 publication-title: Cell Mol Neurobiol doi: 10.1007/s10571-015-0296-1 – ident: 2768_CR50 doi: 10.1016/j.biomaterials.2013.11.083 – volume: 12 start-page: 261 issue: 2 year: 2011 ident: 2768_CR74 publication-title: Curr Pharm Biotechnol doi: 10.2174/138920111794295864 – volume: 39 start-page: 48 issue: 1 year: 2019 ident: 2768_CR62 publication-title: Cancer Commun (Lond) doi: 10.1186/s40880-019-0393-5 – volume: 16 start-page: 1789 issue: 5 year: 2019 ident: 2768_CR52 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.9b00104 – volume: 24 start-page: 179 issue: 3 year: 2014 ident: 2768_CR64 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2013.09.011 – ident: 2768_CR65 doi: 10.1371/journal.pone.0169899 – volume: 21 start-page: 1072 issue: 9 year: 2014 ident: 2768_CR61 publication-title: Bentham Sci – volume: 9 start-page: 755 issue: 3 year: 2020 ident: 2768_CR27 publication-title: Cells doi: 10.3390/cells9030755 – volume: 15 start-page: 3625 issue: 9 year: 2018 ident: 2768_CR44 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.8b00277 – volume: 67 start-page: 11 year: 2017 ident: 2768_CR37 publication-title: Semin Cell Dev Biol doi: 10.1016/j.semcdb.2017.01.003 – volume: 33 start-page: 967 issue: 3 year: 1983 ident: 2768_CR3 publication-title: Cell doi: 10.1016/0092-8674(83)90040-5 – volume: 9 start-page: 19 year: 2019 ident: 2768_CR4 publication-title: Cell Biosci doi: 10.1186/s13578-019-0282-2 – volume: 10 start-page: 367 year: 2019 ident: 2768_CR34 publication-title: Front Genet doi: 10.3389/fgene.2019.00367 – volume: 32 start-page: 2003 issue: 6 year: 2015 ident: 2768_CR51 publication-title: Pharm Res doi: 10.1007/s11095-014-1593-y – volume: 8 start-page: 1332 issue: 8 year: 2018 ident: 2768_CR2 publication-title: Am J Cancer Res – ident: 2768_CR43 doi: 10.1158/1078-0432.CCR-15-2170 – volume: 25 start-page: 1 year: 2018 ident: 2768_CR75 publication-title: Curr Med Chem doi: 10.2174/092986732533181024105122 – volume: 7 start-page: 87081 issue: 52 year: 2016 ident: 2768_CR45 publication-title: Oncotarget doi: 10.18632/oncotarget.13499 – volume: 7 start-page: 789 issue: 3 year: 2017 ident: 2768_CR13 publication-title: Theranostics doi: 10.7150/thno.18133 – volume: 280 start-page: 31 issue: 1 year: 2009 ident: 2768_CR77 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2009.02.011 – volume: 4 start-page: 219 issue: 3 year: 1983 ident: 2768_CR68 publication-title: Oncodev Biol Med – volume: 6 start-page: 11327 issue: 13 year: 2015 ident: 2768_CR21 publication-title: Oncotarget doi: 10.18632/oncotarget.3598 – volume: 7 start-page: 48 issue: 2 year: 2019 ident: 2768_CR33 publication-title: Dent J (Basel) doi: 10.3390/dj7020048 – volume: 6 start-page: 32774 issue: 32 year: 2015 ident: 2768_CR59 publication-title: Oncotarget doi: 10.18632/oncotarget.5192 – volume: 9 start-page: 315 issue: 3 year: 2016 ident: 2768_CR53 publication-title: Cell Mol Bioeng doi: 10.1007/s12195-016-0457-4 – volume: 15 start-page: 1 issue: 1 year: 2019 ident: 2768_CR7 publication-title: Int J Biol Sci doi: 10.7150/ijbs.27796 – volume: 10 start-page: 619 issue: 5 year: 2008 ident: 2768_CR16 publication-title: Nat Cell Biol doi: 10.1038/ncb1725 – volume: 6 start-page: 92 issue: 10 year: 2017 ident: 2768_CR46 publication-title: Foods doi: 10.3390/foods6100092 – volume: 69 start-page: 5601 issue: 13 year: 2009 ident: 2768_CR20 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-3860 – volume: 21 start-page: 185 issue: 1 year: 2013 ident: 2768_CR54 publication-title: Mol Ther doi: 10.1038/mt.2012.180 – volume: 146 start-page: 557 issue: 5 year: 2016 ident: 2768_CR36 publication-title: Histochem Cell Biol doi: 10.1007/s00418-016-1460-5 – volume: 44 start-page: 170 year: 2017 ident: 2768_CR41 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2017.02.006 – volume: 7 start-page: 171 issue: 2 year: 2019 ident: 2768_CR40 publication-title: World J Clin Cases doi: 10.12998/wjcc.v7.i2.171 – volume: 72 start-page: 659 issue: 4 year: 2015 ident: 2768_CR5 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-014-1764-3 – volume: 65 start-page: 157 issue: 2 year: 2013 ident: 2768_CR49 publication-title: J Pharm Pharmacol doi: 10.1111/j.2042-7158.2012.01567.x – volume: 360 start-page: 295 issue: 9329 year: 2002 ident: 2768_CR57 publication-title: Lancet doi: 10.1016/S0140-6736(02)09552-1 – volume: 44 start-page: 2060 issue: 11 year: 2012 ident: 2768_CR55 publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2012.08.007 – volume: 9 start-page: 19 year: 2019 ident: 2768_CR6 publication-title: Cell Biosci doi: 10.1186/s13578-019-0282-2 – volume: 74 start-page: 313 issue: 2 year: 2017 ident: 2768_CR10 publication-title: Infect Diabetes Acta Poloniae Pharmaceutica – ident: 2768_CR24 doi: 10.1007/s10911-020-09473-0 – volume: 1 start-page: 1 year: 2011 ident: 2768_CR76 publication-title: Stem Cell Rev Reports doi: 10.1007/s12015-010-9166-x – volume: 22 start-page: 758 issue: 5 year: 2013 ident: 2768_CR66 publication-title: Stem Cells Dev doi: 10.1089/scd.2012.0304 – ident: 2768_CR1 doi: 10.3322/caac.21492 – volume: 14 start-page: 58 issue: 1 year: 2015 ident: 2768_CR15 publication-title: Mol Cancer doi: 10.1186/s12943-015-0327-z – volume: 40 start-page: 41 year: 2015 ident: 2768_CR19 publication-title: Semin Cell Dev Biol doi: 10.1016/j.semcdb.2015.02.010 – volume: 60 start-page: 38 year: 2018 ident: 2768_CR23 publication-title: Mol Aspects Med doi: 10.1016/j.mam.2017.12.003 – volume: 38 start-page: 317 issue: 1 year: 2019 ident: 2768_CR28 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-019-1317-6 – volume: 36 start-page: 888 issue: 8 year: 2010 ident: 2768_CR17 publication-title: Semin Thromb Hemost doi: 10.1055/s-0030-1267043 – volume: 21 start-page: 52 issue: 1 year: 2019 ident: 2768_CR31 publication-title: Int J Mol Sci doi: 10.3390/ijms21010052 – volume: 9 start-page: 1837 issue: 1 year: 2019 ident: 2768_CR79 publication-title: Sci Rep doi: 10.1038/s41598-018-38320-w – volume: 17 start-page: 59 issue: 2 year: 2002 ident: 2768_CR73 publication-title: J Tumor Marker Oncol. – volume: 21 start-page: 5840 issue: 16 year: 2020 ident: 2768_CR9 publication-title: Int J Mol Sci doi: 10.3390/ijms21165840 – volume: 52 start-page: e12659 issue: 6 year: 2019 ident: 2768_CR32 publication-title: Cell Prolif doi: 10.1111/cpr.12659 – volume: 5 start-page: 81 issue: 4 year: 2017 ident: 2768_CR56 publication-title: Ann Transl Med doi: 10.21037/atm.2017.01.50 – volume: 119 start-page: 1159 issue: 6 year: 2012 ident: 2768_CR14 publication-title: Cancer doi: 10.1002/cncr.27895 – volume: 17 start-page: 495 issue: 3 year: 2018 ident: 2768_CR35 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.RA117.000267 – volume: 11 start-page: 1617 issue: 9 year: 2006 ident: 2768_CR71 publication-title: Apoptosis doi: 10.1007/s10495-006-8895-4 – volume: 12 start-page: 9 issue: 4 year: 1977 ident: 2768_CR72 publication-title: J Tum Marker Oncol – volume: 7 start-page: 1505403 issue: 1 year: 2018 ident: 2768_CR29 publication-title: J Extracell Vesicles doi: 10.1080/20013078.2018.1505403 |
| SSID | ssj0024549 |
| Score | 2.3605218 |
| SecondaryResourceType | review_article |
| Snippet | Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing... Exosomes are nanoparticle sized (100 [+ or -] 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by... Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing... Abstract Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 103 |
| SubjectTerms | Amniotic fluid Apoptosis Bioavailability Biomarkers Biomedical and Life Sciences Biomedical engineering Biomedicine Biosynthesis Cancer Care and treatment Cell differentiation Cell interactions Cell organelles Colorectal cancer Combination strategies Cytosomes Degenerative diseases Drug delivery Drug Delivery Systems Exosomes Extracellular Vesicles Gastric cancer Gene expression Health aspects Humans Immune system Immunomodulation Immunosuppressive agents Liver cancer Medical diagnosis Medical prognosis Medicine/Public Health Metastasis Methods Microenvironments Nanoparticles Neoplasms - drug therapy Nuclear reprogramming Pancreatic cancer Paracrine signalling Physiological aspects Prostate cancer Proteins Regenerative Medicine Reprogramming Review Signaling Stem cells Therapy Toxicity Tumor Microenvironment Vesicles |
| SummonAdditionalLinks | – databaseName: DOAJ dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07b9cwELdQB8SCeBMolZGQGCBq4rfHUrWqkMpERTfLsR1RiSao-bcq354750FTBCys8dmx7873SM4_E_JGh6Rti9UzTEOCwmxb2mCq0lY-1k1swUngd8jjT-roRHw8lac3rvrCmrARHnhk3G4DIUaU0jQhMNGg8ZQsWh94spUyPh_zBTc2J1Mzyh6kPfMRGaN2B_BqYBCwHAHSMGVKs3JDGa3_d5t8wyndLpi89dc0O6PDB-T-FEXSvXH2D8md1D0id4-n_-SPyZeDBcSb9i1N1_3QnycaQd2uMtL3QP1Am7O-nIBTxy-CFCEuc73WObyWjmezflCgoAG14-IJOTk8-Lx_VE5XKJRBVXoDti5WLWQMmkUTfSN80KkOurHWa0wemPYpCql13Qb01olVSVhw4nViOkHs8pRsdX2XnhMaUgRJ-FbHqEWMkGbIKBEtx_JY1UEVpJ456sKEL47XXHxzOc8wyo1ScCAFl6XgTEHeLX2-j-gaf6X-gIJaKBEZOz8AfXGTvrh_6UtB3qKYHbIXphf8dAwBFolIWG5PScmEUlYWZHtFCfsurJtnRXHTvh8cBJTMQgrMeEFeL83YE2vZutRfZhrBuYVhCvJs1KtlSZwj3H6tC6JXGrda87qlO_uaUcHBsArFYcz3s27-mtafefrif_D0JbnH8t7iZWW3ydbm4jK9glht0-zkbfkT9pM4Wg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86QXwRv61OiSD4oGVtmo_mSaZsDGE-ObxvIU1SHWztvL0T_e89J0177cS9Nqdpk_OdnPxCyGvlgtItVs8wBQkK022uXV3kurC-bHwLTgLXIY8_y6MT_mklVmnBbUhllZNNjIba9w7XyPfAVTMNyQWr3l_8yPHWKNxdTVdo3CS3SghVUKrVaptwcUh-poMytdwbwLeBWcCiBEjGZJ3XC2cUMfv_tcx_uaarZZNX9k6jSzq8R-6mWJLuj8y_T26E7gG5fZx2yx-SrwczlDftWxp-9UN_HqgHofsZ8b4HagfanPZ5gk8d1wUpAl3Gqq1z-CwdT2j9pkBBHcrI-hE5OTz48vEoTxcp5E4WagMWzxct5A2K-drbhlunQulUo7VVmEIwZYPnQqmydeizAysC1-DKy8BUgAjmMdnp-i48JdQFX2pvW-W94t5DsiG8QMwcXfmidDIj5TSjxiWUcbzs4szEbKOWZuSCAS6YyAVTZ-Tt_M7FiLFxLfUHZNRMifjY8UG__maSupkGAlMvRN04x3iDLlcwr62rgi5kbaGTN8hmg9MLv-dsOowAg0Q8LLMvhWBcSi0ysrugBO1zy-ZJUEzS_sFsZTUjr-ZmfBMr2rrQX0YaXlUausnIk1Gu5iFVFYLulyojaiFxizEvW7rT7xEbHMwrlxX0-W6Sze1v_X9On10_iufkDotaU-WF3iU7m_VleAGx2KZ5GRXuD8wLMAE priority: 102 providerName: ProQuest – databaseName: Springer Nature Link dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9cgECc6E-OL8bfVaTAx8UEbCxQoj_ObLYvJfHJxb4QCjUtcu6zfGfff747y7db5I_G1HBS4O-4Ojg-EvNU-atNh9gzXEKBw05XGN1VpKhdYGzowErgPefBF7R_Wn4_kUYbJwbsw18_vWaM-jmCPQJUxkQACKNWUzW1yR8LCi-l7K7W6wtWDQGdzKeaP9RaGJ-Hz_74KXzNDN1Mkb5yTJvOz94Dcz34j3ZkY_ZDciv0jcvcgn4w_Jt92Z9huOnQ0_hrG4STSAAL2M2F7j9SNtD0eygyVOu0BUgS1TBlaJ_BbOt3GuqBAQT3Kw9kTcri3-3W1X-ZHE0qvKr2G1S1UHcQImocmuLZ2XkfmdWuM0xgucO1iqKXWrPNonyOvYm3AbLPIdQRv5SnZ6oc-PifUx8BMcJ0OQdchQGAhg0R8HCNCxbwqCNvMqPUZURwftvhhU2TRKDtxwQIXbOKCbQryfq5zOuFp_JP6EzJqpkQs7PQBRMRm1bItOKFByqb1ntctmlfJg3FeRFOpxkEj75DNFqcXuuddvngAg0TsK7ujpOS1UkYWZHtBCZrml8UbQbFZ00cLLiQ3EPRyUZA3czHWxOy1Pg7niaYWwkAzBXk2ydU8JCEQYJ_pguiFxC3GvCzpj78nHHBYSmsloM0PG9m86tbf5_TF_5G_JPd40iJRVmabbK3PzuMr8MPW7eukgJdTTykB priority: 102 providerName: Springer Nature |
| Title | Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer |
| URI | https://link.springer.com/article/10.1186/s12967-021-02768-8 https://www.ncbi.nlm.nih.gov/pubmed/33750417 https://www.proquest.com/docview/2502919123 https://www.proquest.com/docview/2504339524 https://pubmed.ncbi.nlm.nih.gov/PMC7944634 https://doaj.org/article/b519d558bcc24b299052d9ac3e9068a8 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: KQ8 dateStart: 20030701 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: KQ8 dateStart: 20030101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: ABDBF dateStart: 20030101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: DIK dateStart: 20030101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RPM dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1479-5876 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: M48 dateStart: 20031201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: AAJSJ dateStart: 20030601 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: C6C dateStart: 20030601 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED_6AaUvY99z1wUNBnvYvNmyLVkPYzQhpQxSRllY2IuwJbkrtPYap6P973eSPzJ37V4MsT4i6e50d_LpdwBvuDJcFDZ6hnJ0UKgofKHSwBdBpsNcF6gk7Dnk7JgdzeMvi2SxAV26o3YB6ztdO5tPar48_3B9efMZBf6TE_iUfaxRZ6G422ADdLJY6qebsI2aiVoun8XpGnsPnaHu4syd7XZhJ4os4LnLX7bWUw7O_99N-y-tdTui8tZnVaetDh_Cg9bMJAcNXzyCDVM-hp1Z-yH9CXyf9ijfpCqIua7q6sIQjfz420GB1ySrSX5W-S2yanNkSCwGpgvousC_Jc3lrRuCNYiy7LN8CvPD6bfJkd_mWPAVC_gKN0MdFOhScKpTneVxprgJFc-FyLj1LijPjI4TzsNCWXVuaGBigVo-NJQbNG6ewVZZleYFEGV0KHRWcK15rDX6IYlOLJyOiHQQKuZB2K2oVC0Auc2DcS6dI5Iy2RBEIkGkI4hMPXjXt_nVwG_8t_bYEqqvaaGz3YtqeSpbSZQ52qw6SdJcKRrnVhsnVItMRUYELM2wk7eWzNIuLw5PZe09BZykhcqSByxJaMyYSDzYH9REwVTD4o5RZMfXEi1OKtBHppEHr_ti29IGu5WmunJ14igS2I0Hzxu-6qfUsacHfMBxgzkPS8qznw42HHfemEXY5_uON9fDun9N9-4dwkvYpU52Ij8Q-7C1Wl6ZV2ihrfIRbPIFH8H2eHr89QR_Tdhk5E47Rk4g8Xky_vEHBYc4fA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXxJuUAkYCcYCoiePY8QGhAq22tNtTK_ZmEtuBSm1SNlugf4rfyIzzWFJEb73GEyf2vDz2-BtCXkjjpCoxe4ZJCFCYKkNlsihUUW7jwpbgJHAfcrovJof80yydrZDf_V0YTKvsbaI31LY2uEe-Aa6aKQguWPLu9HuIVaPwdLUvodGKxa47_wkhW_N25yPw9yVj21sHHyZhV1UgNCKSC1B_G5WwiJbMZjYveG6ki40slMolrqeZzJ3lqZRxadCBORY5rsCvxY5JpxB8CUz-NZ5EHLH65WwZ4HEItvqLOZnYaMCXghnCJAgI_kQWZiPn52sE_OsJ_nKFF9M0L5zVehe4fZvc6taudLMVtjtkxVV3yfVpdzp_j3zeGqDDaV1S96tu6hNHLQj5D48v3tC8ocVRHXZwre0-JEVgTZ8ldgKfpe2NsHMKFNSgTM7vk8MrmeIHZLWqK_eIUONsrGxeSmsltxaCm9SmiNGjEhvFRgQk7mdUmw7VHItrHGsf3WRCt1zQwAXtuaCzgLwe3jltMT0upX6PjBooEY_bP6jnX3Wn3rqAhbBN06wwhvECXXzKrMpN4lQkshw6eYVs1ji98Hsm7y4_wCARf0tvijRlXAiVBmR9RAnabsbNvaDozto0eqkbAXk-NOObmEFXufrM0_AkUdBNQB62cjUMKUkQ5D-WAZEjiRuNedxSHX3zWORgzrlIoM83vWwuf-v_c7p2-SiekRuTg-me3tvZ331MbjKvQUkYqXWyupifuSewDlwUT73yUfLlqrX9Dx8Qa7M |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVqq4VLxJKWAkJA4QNXHi13GBrspCKySo6M1KbAcq0aTabBH8e8bOo015SFzjsRN7Zjwz9swXgGfCOKEqnz1DBQYoVFWxMjKJVVLYtLQVGgl_DnlwyPeP8uUxO75UxR-y3Ycrya6mwaM01evdM1t1Ki75botWChXcpxdgWMVlLK_DhmT4bAYb8_ny4_ICbw8DoKFY5o89JwYp4Pb_vjtfMk9XUyev3J8Gs7S4CVu9P0nmnQDcgmuuvg2bB_2N-R34vDfCeZOmIu5H0zanjlgUvO8B87slRUvKkybuIVS7s0HiwS5D5tYpvpZ0VVo_CVIQ4-VkdReOFnufXu_H_c8UYsMTscZdzyYVxg6CWmmLMi-McKkRpVKF8GEEFYWzORMirYy3244mLldozlNHhUMv5h7M6qZ2D4AYZ1Nli0pYK3JrMeBglnncHJXZJDU8gnRYUW16pHH_w4tvOkQckuuOCxq5oAMXtIzgxdjnrMPZ-Cf1K8-okdJjZIcHzeqL7lVOl-icWsZkaQzNS292GbWqMJlTCZcFDvLcs1n75cXPM0VfkICT9JhYes4ZoznnikWwM6FEDTTT5kFQdL8DtBpdS6owGKZZBE_HZt_TZ7XVrjkPNHmWKRwmgvudXI1TyjIPvJ-KCMRE4iZznrbUJ18DPjhusTnPcMyXg2xefNbf13T7_8ifwOaHNwv9_u3hu4dwgwaFyuJE7cBsvTp3j9BVW5ePe238Bah7Naw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+exosome+derivatives+as+bio-informational+reprogramming+therapy+for+cancer&rft.jtitle=Journal+of+translational+medicine&rft.au=Gonzalez%2C+Michael+J&rft.au=Kweh%2C+Mercedes+F&rft.au=Biava%2C+Pier+Mario&rft.au=Olalde%2C+Jose&rft.date=2021-03-09&rft.eissn=1479-5876&rft.volume=19&rft.issue=1&rft.spage=103&rft_id=info:doi/10.1186%2Fs12967-021-02768-8&rft_id=info%3Apmid%2F33750417&rft.externalDocID=33750417 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |